The recent development of molecular targeted therapy for tumor is a new therapeutic field based on the understanding of genes and receptors, which has a very important prospect. In fact, traditional cytotoxic chemotherapeutic drugs also have their own targets, only that these targets are not specific to tumors, which is why the phenomenon of “not distinguishing between the enemy and us” has appeared in the clinic. In recent years, with the improvement of molecular biology technology and the further understanding of tumor pathogenesis from the molecular level of cell receptors and proliferation regulation, the use of targeted drugs to close the key targets in the process of tumor development and to correct its pathological process, to regulate and stabilize the tumor cells, has achieved very good results in the clinic. At present, the main targets of biotargeted therapy include: blocking cell signaling pathway (acting on cell surface receptors and intracellular regulatory proteins).